----item----
version: 1
id: {8182E2A3-3A8A-455E-A6A5-7F0301807F94}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/08/05/Celgene Opts Into GlobeImmune Drug
parent: {27CA359C-D6DE-4338-B805-0D8ED1E4FF56}
name: Celgene Opts Into GlobeImmune Drug
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: c99f3760-4874-49e9-9912-ea7841d1c989

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 34

Celgene Opts Into GlobeImmune Drug
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 34

Celgene Opts Into GlobeImmune Drug
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1064

<p><p>Big biotech Celgene has opted into an exclusive license agreement with GlobeImmune for its Phase II cancer drug GI6207, which targets cancers that express carcinoembryonic antigen. GlobeImmune received a payment of $1.8m for the decision. </p><p>The pair originally inked the deal in May 2009 when Celgene paid $40m upfront and agreed to $500m in development milestones, as well as double digit royalties. The upfront payment included a $10m equity investment. </p><p>Previously, Celgene opted not to exercise its option on the lead compound in the deal, GI4000, which was being studied in patients with pancreatic cancer. </p><p>GlobeImmune debuted on the public market in 2012 after successfully garnering several big biotech and pharma partners. Not all of the partnerships have been as fruitful; Gilead recently pulled out of a partnership with the company for a hepatitis B drug that <a href="http://#http://www.scripintelligence.com/home/New-partner-for-Gilead-after-GlobeImmune-failure-358623" target="_new">failed in a mid-stage</a> study. </p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 34

Celgene Opts Into GlobeImmune Drug
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150805T182005
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150805T182005
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150805T182005
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029432
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 34

Celgene Opts Into GlobeImmune Drug
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{2D771726-4AE8-4124-B380-232612225CB7}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359700
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042432Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c99f3760-4874-49e9-9912-ea7841d1c989
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042432Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
